Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GHSI Guardion Health Sciences	$3.22 -2.1%	$3.24	$3.04 ▼ $18.00	$4.35M	0.73	105,261 shs	4,700 shs
PVCT Provectus Biopharmaceuticals	$0.08	$0.08	$0.04 ▼ $0.15	$32.15M	0.75	152,537 shs	117,590 shs
RGLS Regulus Therapeutics	$8.16	$8.04	$0.83 ▼ $8.35	$564.92M	0.35	996,921 shs	N/A
SXTC China SXT Pharmaceuticals	$1.75 +2.3%	$1.73	$0.95 ▼ $11.92	$198.41M	1.18	1.19 million shs	46,053 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GHSI Guardion Health Sciences	0.00%	0.00%	0.00%	0.00%	-67.51%
PVCT Provectus Biopharmaceuticals	0.00%	-1.80%	-3.16%	-22.73%	-41.15%
RGLS Regulus Therapeutics	0.00%	0.00%	+0.12%	+358.43%	+363.64%
SXTC China SXT Pharmaceuticals	+2.34%	-4.11%	-10.26%	-29.72%	-79.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GHSI Guardion Health Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PVCT Provectus Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	1.5035 of 5 stars	2.1	5.0	0.0	0.0	0.0	3.3	0.0
SXTC China SXT Pharmaceuticals	0.8841 of 5 stars	0.0	5.0	0.0	0.0	2.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GHSI Guardion Health Sciences	0.00	N/A	N/A	N/A
PVCT Provectus Biopharmaceuticals	0.00	N/A	N/A	N/A
RGLS Regulus Therapeutics	2.29	Hold	$8.50	4.17% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SXTC, RGLS, GHSI, and PVCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/1/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$9.00
4/30/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$7.00
4/30/2025	RGLS Regulus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$28.00 ➝ $11.00
4/30/2025	RGLS Regulus Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$8.00 ➝ $7.00

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GHSI Guardion Health Sciences	$12.25M	0.35	$0.14 per share	23.15	$6.39 per share	0.50
PVCT Provectus Biopharmaceuticals	$620K	51.86	N/A	N/A	($0.01) per share	-7.65
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	$1.17 per share	N/A
SXTC China SXT Pharmaceuticals	$1.93M	105.21	N/A	N/A	$243.66 per share	0.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GHSI Guardion Health Sciences	$160K	$4.87	0.66	∞	N/A	22.79%	-73.69%	-48.17%	N/A
PVCT Provectus Biopharmaceuticals	-$4.76M	N/A	0.00	∞	N/A	-815.81%	N/A	-644.80%	8/11/2025 (Estimated)
RGLS Regulus Therapeutics	-$46.36M	-$0.73	N/A	N/A	N/A	N/A	-57.53%	-53.26%	8/6/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest SXTC, RGLS, GHSI, and PVCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	RGLS Regulus Therapeutics	-$0.29	-$0.15	+$0.14	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GHSI Guardion Health Sciences	$5.00	155.28%	N/A	102.67%	N/A
PVCT Provectus Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GHSI Guardion Health Sciences	N/A	16.68	16.59
PVCT Provectus Biopharmaceuticals	N/A	0.11	0.11
RGLS Regulus Therapeutics	N/A	16.31	16.31
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GHSI Guardion Health Sciences	20.21%
PVCT Provectus Biopharmaceuticals	0.05%
RGLS Regulus Therapeutics	92.38%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
GHSI Guardion Health Sciences	1.32%
PVCT Provectus Biopharmaceuticals	14.70%
RGLS Regulus Therapeutics	4.35%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GHSI Guardion Health Sciences	10	1.35 million	1.33 million	Not Optionable
PVCT Provectus Biopharmaceuticals	4	420.28 million	358.50 million	Not Optionable
RGLS Regulus Therapeutics	30	69.23 million	66.22 million	Optionable
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable

SXTC, RGLS, GHSI, and PVCT Headlines

Recent News About These Companies

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock Price Down 10.1% - Here's Why

July 8, 2025 | marketbeat.com

China SXT Pharmaceuticals, Inc. (SXTC) - Yahoo Finance

July 4, 2025 | sg.finance.yahoo.com

China SXT Pharmaceuticals Inc News (SXTC) - Investing.com

June 25, 2025 | investing.com

China SXT Pharmaceuticals Issues 90 Million Shares Following Warrant Exercise

June 16, 2025 | tipranks.com

China SXT Pharmaceuticals Inc Ordinary Shares

April 23, 2025 | morningstar.comM

China SXT Pharmaceuticals Reports Financial Results Amid Regulatory Challenges

March 28, 2025 | tipranks.com

China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange

March 19, 2025 | tipranks.com

China SXT Pharmaceuticals regains compliance with Nasdaq

March 17, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

March 17, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

March 17, 2025 | globenewswire.com

China SXT Pharmaceuticals Inc trading resumes

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, volatility trading pause

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, news pending

February 24, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Announces New Securities Purchase Agreement

January 27, 2025 | msn.com

China SXT Pharmaceuticals Inc (SXTC) Stock’s 0.02% Increase This Year: What’s the Story?

January 7, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock Price Reaches $0.51: What Factors Are Influencing This Level?

January 1, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock: Greater Than Its Current Valuation?

December 26, 2024 | bovnews.comB

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

October 7, 2024 | globenewswire.com

china sxt pharmaceuticals - SXTC

October 3, 2024 | foxbusiness.com

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock, Short Interest Report

October 1, 2024 | benzinga.com

Can China SXT Pharmaceuticals Inc (SXTC) Stock rise from its doldrums?

July 24, 2024 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, RGLS, GHSI, and PVCT Company Descriptions

Guardion Health Sciences NASDAQ:GHSI

Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.

Provectus Biopharmaceuticals OTCMKTS:PVCT

$0.08 0.00 (0.00%)

As of 07/11/2025 03:52 PM Eastern

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

Regulus Therapeutics NASDAQ:RGLS

$8.16 0.00 (0.00%)

As of 06/25/2025

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.75 +0.04 (+2.34%)

Closing price 07/11/2025 03:59 PM Eastern

Extended Trading

$1.77 +0.02 (+1.14%)

As of 07/11/2025 07:35 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time